Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;88(18):10894-908.
doi: 10.1128/JVI.01477-14. Epub 2014 Jul 9.

Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells

Affiliations

Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells

S E Jackson et al. J Virol. 2014 Sep.

Abstract

CD8(+) T cells specific for pp65, IE1, and IE2 are present at high frequencies in human cytomegalovirus (HCMV)-seropositive individuals, and these have been shown to have phenotypes associated with terminal differentiation, as well as both cytokine and proliferative dysfunctions, especially in the elderly. However, more recently, T cell responses to many other HCMV proteins have been described, but little is known about their phenotypes and functions. Consequently, in this study, we chose to determine the diversity of HCMV-specific CD8(+) T cell responses to the products of 11 HCMV open reading frames (ORFs) in a cohort of donors aged 20 to 80 years old as well as the ability of the T cells to secrete gamma interferon (IFN-γ). Finally, we also tested their functional antiviral capacity using a novel viral dissemination assay. We identified substantial CD8(+) T cell responses by IFN-γ enzyme-linked immunospot (ELISPOT) assays to all 11 of these HCMV proteins, and across the cohort, individuals displayed a range of responses, from tightly focused to highly diverse, which were stable over time. CD8(+) T cell responses to the HCMV ORFs were highly differentiated and predominantly CD45RA(+), CD57(+), and CD28(-), across the cohort. These highly differentiated cells had the ability to inhibit viral spread even following direct ex vivo isolation. Taken together, our data argue that HCMV-specific CD8(+) T cells have effective antiviral activity irrespective of the viral protein recognized across the whole cohort and despite viral immune evasion.

Importance: Human cytomegalovirus (HCMV) is normally carried without clinical symptoms and is widely prevalent in the population; however, it often causes severe clinical disease in individuals with compromised immune responses. HCMV is never cleared after primary infection but persists in the host for life. In HCMV carriers, the immune response to HCMV includes large numbers of virus-specific immune cells, and the virus has evolved many mechanisms to evade the immune response. While this immune response seems to protect healthy people from subsequent disease, the virus is never eliminated. It has been suggested that this continuous surveillance by the immune system may have deleterious effects in later life. The study presented in this paper examined immune responses from a cohort of donors and shows that these immune cells are effective at controlling the virus and can overcome the virus' lytic cycle immune evasion mechanisms.

PubMed Disclaimer

Figures

FIG 1
FIG 1
The HCMV ORF-specific diversity of CD8+ T cell responses varies widely between donors. The frequency of the CD8+ T cell responses to 11 HCMV ORF products in 18 donors is shown. The responses were measured by IFN-γ ELISPOT assay and are shown as SFU/million cells following the subtraction of background counts from unstimulated cells. (A) The donor cohort is arranged according to the ages of the donors, and the size of the response to each HCMV ORF product is shown as a heat map. (B) Number of ORF products each donor responded to (>100 SFU/million); (C) the same numbers plotted according to the ages of the donors. There was no statistical correlation between age and the number of ORF products an individual recognized by Pearson's correlation. (D) The cumulative IFN-γ response to all HCMV ORF products for each donor was plotted according to donor age, and this was not significantly correlated with age by Spearman's correlation. (E) The number of ORF products each donor responded to at high frequency (>1,000 SFU/million) was also correlated with age by Pearson's correlation; there is a significant increase in high-frequency responses to ORF products in older donors (P = 0.02). (F and G) The frequency of recognition by CD8+ T cells of each HCMV ORF product is shown for all responses of >100 SFU/million (F) and the high-frequency responses (>1,000 SFU/million) (G; a subset of the data in panel F). The HCMV ORFs were ranked according to the number of subjects responding.
FIG 2
FIG 2
The frequency and diversity of HCMV ORF CD8+ T cell responses were not significantly changed over time. HCMV ORF-specific T cell frequency was determined for 18 donors in 2009 by IFN-γ ELISPOT and then determined again for 11 donors in 2011 (24 months) and again for 7 donors in 2012 (36 months). The responses for each ORF are shown for the 24-month (A) and the 36-month (B) data. The positive-response cutoff (dashed line) is 100 SFU/million. The 24-month paired data were tested using a Wilcoxon matched-pairs test; significant results (*, P < 0.05) are indicated. The 3 time points in the 36-month data group were tested using a 1-way ANOVA with a paired Friedman's test, which showed no significant change in the variance of the data.
FIG 3
FIG 3
There is fluctuation in the magnitude of an individual donor's CD8+ T cell response to particular HCMV ORFs. HCMV ORF-specific T cell frequency was determined by IFN-γ ELISPOT at multiple time points over a 40-month period. (A) The responses of 5 different donors corresponding to HCMV ORFs UL83 (pp65), UL82 (pp71), UL123 (IE1), and US3 show that for an individual, the magnitude of the response both decreases and increases during the period of time observed. (B) Responses of donors CMV305, CMV300, and CMV301 to selected HCMV ORFs for the same period. The positive-response cutoff (dashed line) is 100 SFU/million.
FIG 4
FIG 4
HCMV-specific CD8+ T cells have a predominantly CD45RA+ CD27 (TEMRA) phenotype. PBMC were stimulated overnight with mapped HCMV ORF peptides or HCMV ORF peptide pools in the presence of brefeldin A. (A) Identification of HCMV-specific CD8+ T cell responses was as shown in the example of gating strategy. (B) Antigen-specific CD8+ populations were identified by expression of 4-1BB and CD69, and 4 memory populations were defined according to the expression of CD27 and CD45RA (CD27+ CD45RA+, CD27+ CD45RA [TCM], CD27 CD45RA [TEM], and CD27 CD45RA+ [TEMRA] cells). (B) Comparison of the CD27 and CD45RA phenotype of mapped peptide-stimulated 4-1BB- and CD69-positive CD8+ T cells with matched pentamer identified CD8+ T cells. (C) The memory phenotypes of T cells specific for the products of 6 HCMV ORFs (pp65, pp71, UL28, IE1, IE2, and US3) identified by expression of CD69 and 4-1BB for 6 donors were examined. The data for each ORF are arranged in order of increasing donor age from left to right on the x axis (C).
FIG 5
FIG 5
CD8+ T cells specific to products of 6 different HCMV ORFs had very similar patterns of IFN-γ secretion. PBMC from 6 donors were stimulated overnight with mapped HCMV ORF peptides or HCMV ORF peptide pools in the presence of brefeldin A. (A) Antigen-specific populations were identified as described in the legend to Fig. 5. (B) IFN-γ production by the TEMRA antigen-specific CD8+ T cell subset was determined. The proportion of the HCMV-specific TEMRA population which secreted IFN-γ (black) as a proportion of the total percentage of antigen-specific TEMRA cells (gray) for the different HCMV ORFs examined (pp65, pp71, UL28, IE1, IE2, and US3) are shown; the data for each ORF are arranged in order of increasing donor age from left to right on the x axis. The proportion of HCMV-specific TEMRA cells which secreted IFN-γ varied between donors, but there was no relationship with either age or HCMV ORF specificity.
FIG 6
FIG 6
HCMV-CD8+ T cells specific for pp65, IE1, pp71, UL28, US3, and IE2 mediated cytotoxicity. HCMV-specific CD8+ T cells were used as effector cells in chromium release assays to determine the cytotoxicity function of cells specific for pp65, IE1, pp71, UL28, US3, and IE2. Target cells were donor-matched lymphoblastoid B cell lines which were pulsed with mapped peptides for each donor's known HCMV ORF responses or not pulsed. CD8+ T cells specific to all the HCMV ORFs examined show specific lysis of peptide-pulsed target cells compared to activity against unpulsed target cells.
FIG 7
FIG 7
Both pp65- and IE1-specific CD8+ T cells control viral dissemination in an in vitro assay. Donor-matched dermal fibroblasts were infected with TB40e-UL32-GFP virus at a low MOI, and HCMV-specific in vitro-expanded CD8+ T cells were cocultured with the virus-infected fibroblasts at a range of effector-to-target cell ratios. The percentage of GFP-positive fibroblasts was measured by flow cytometry at 14, 21, and 28 days in comparison to an uninfected control, an infected control, and a nonspecific CD8+ T cell line (EBV specific). (A and B) A representative example from donor CMV307 at day 14 of the assay was used to generate dot plots (A) and a summarized bar chart (B), with data expressed as a proportion of the infected control for pp65- and IE1-specific CD8+ T cells, which are both equally able to control dissemination of virus. (C) CD8+ T cells obtained directly ex vivo from HLA-matched CMV-seropositive and -seronegative donors were cocultured with the virus-infected fibroblasts, and the percentages of GFP-positive fibroblasts as a proportion of the infected control at day 21 of the assay are shown. (D) HCMV-specific CD8+ pentamer-sorted cells obtained directly ex vivo at effector-to-target cell ratios of 0.14:1 and 0.08:1 were able to control the dissemination of virus. Data shown are from day 21 of the assay.
FIG 8
FIG 8
UL82- and US3 -CD8+ T cells control viral dissemination in an in vitro assay. Donor-matched dermal fibroblasts were infected with TB40e-UL32-GFP at a low MOI. HCMV-specific in vitro-expanded CD8+ T cells were cocultured with the virus-infected fibroblasts at a range of effector-to-target cell ratios as described for Fig. 6. (A and B) Summary bar charts showing the percentages of GFP-positive fibroblasts present at day 21 for UL82 (A)- and US3 (B)-specific CD8+ T cells compared to UL83 (pp65)- and UL123 (IE1)-specific cells, respectively (expressed as a proportion of the infected control). Both UL82- and US3-specific CD8+ T cells are able to control dissemination of virus in this assay.

Similar articles

Cited by

References

    1. Gandhi MK, Khanna R. 2004. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4:725–738. 10.1016/S1473-3099(04)01202-2 - DOI - PubMed
    1. Sinclair J, Sissons P. 2006. Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 87:1763–1779. 10.1099/vir.0.81891-0 - DOI - PubMed
    1. Riddell SR, Kathe SW, Goodrich JM, Li CR, Agha ME, Greenberg PD. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241. 10.1126/science.1352912 - DOI - PubMed
    1. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038–1044. 10.1056/NEJM199510193331603 - DOI - PubMed
    1. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916–3922. 10.1182/blood.V99.11.3916 - DOI - PubMed

Publication types

Substances